Evidence map›Paper›PMID 26352511›Full record

ArticleAIDS research and human retroviruses2016

Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada.

John R Koethe, Cathy A Jenkins, Bryan Lau, Bryan E Shepherd, Amy C Justice, Janet P Tate, Kate Buchacz, Sonia Napravnik, Angel M Mayor, Michael A Horberg and 12 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04903847 (Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2), which is not on this map. Cited by 187 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04903847 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2

TypeinterventionalSponsorThomas BenfieldRan2021 to 2023Enrolled126ConditionsHiv, HIV Infections, HIV Lipodystrophy, OsteoporosisArmsDolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Weight gain, obesity, and the impact of lifestyle factors among people living with HIV: A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  17. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  18. Trial
  19. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  20. Trial

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

John R Koethe1 Vanderbilt University School of Medicine , Nashville, Tennessee.
Cathy A Jenkins1 Vanderbilt University School of Medicine , Nashville, Tennessee.
Bryan Lau2 Johns Hopkins University , Baltimore, Maryland.
Bryan E Shepherd1 Vanderbilt University School of Medicine , Nashville, Tennessee.
Amy C Justice3 Yale School of Medicine , New Haven, Connecticut.
Janet P Tate3 Yale School of Medicine , New Haven, Connecticut.
Kate Buchacz5 Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention , Atlanta, Georgia .
Sonia Napravnik6 University of North Carolina , Chapel Hill, North Carolina.
Angel M Mayor7 Universidad Central del Caribe , Bayamon, Puerto Rico .
Michael A Horberg8 Mid-Atlantic Permanente Research Institute , Rockville, Maryland.
Aaron J Blashill9 Harvard Medical School , Boston, Massachusetts.
Amanda Willig10 University of Alabama at Birmingham , Birmingham, Alabama.
C William Wester1 Vanderbilt University School of Medicine , Nashville, Tennessee.
Michael J Silverberg11 Kaiser Permanente Northern California , Oakland, California.
John Gill12 Alberta HIV Clinic , Sheldon M. Chumir Health Centre, Calgary, Alberta, Canada .
Jennifer E Thorne2 Johns Hopkins University , Baltimore, Maryland.
Marina Klein13 McGill University Health Center , Montreal, Quebec, Canada .
Joseph J Eron6 University of North Carolina , Chapel Hill, North Carolina.
Mari M Kitahata14 University of Washington , Seattle, Washington.
Timothy R Sterling1 Vanderbilt University School of Medicine , Nashville, Tennessee.
Richard D Moore2 Johns Hopkins University , Baltimore, Maryland.
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)

Funding

WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
NATURAL HISTORY OF AIDS IN HOMOSEXUAL MENU01AI035040 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DETELS, ROGER, MARTINEZ-MAZA, OTONIEL · 1993 to 2018
$75.2M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)U01AI035041 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARTINSON, JEREMY JAMES, RINALDO, CHARLES R · 1993 to 2018
$71.4M
CIHR CBR-86906CIHR CBR-94036CIHR HCP-97105CIHR KRS-86251CIHR TGF-96118FIC NIH HHS D43 TW000010Intramural CDC HHS CC999999NCATS NIH HHS KL2 TR000421NCATS NIH HHS KL2 TR002317NCATS NIH HHS UL1-TR000083NCI NIH HHS N02-CP55504NCRR NIH HHS M01-RR-00052NCRR NIH HHS UL1-RR024131NCRR NIH HHS UL1-RR024975-01NIAAA NIH HHS R01-AA16893NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U24 AA020794NIAAA NIH HHS U24 AA022001NIAID NIH HHS AI54999NIAID NIH HHS K23 AI100700NIAID NIH HHS K24-AI65298NIAID NIH HHS P30 AI027763NIAID NIH HHS P30-AI027763NIAID NIH HHS P30 AI036219NIAID NIH HHS P30-AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI094189NIAID NIH HHS P30-AI094189NIAID NIH HHS P30-AI27757NIAID NIH HHS P30-AI27767NIAID NIH HHS P30-AI50410NIAID NIH HHS R24-AI067039NIAID NIH HHS R56-AI102622NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI069918NIAID NIH HHS U01-AI31834NIAID NIH HHS U01-AI34989NIAID NIH HHS U01-AI34993NIAID NIH HHS U01-AI34994NIAID NIH HHS U01-AI35004NIAID NIH HHS U01-AI35039NIAID NIH HHS U01-AI35040NIAID NIH HHS U01-AI35041NIAID NIH HHS U01-AI35042NIAID NIH HHS U01-AI35043NIAID NIH HHS U01-AI37613NIAID NIH HHS U01-AI37984NIAID NIH HHS U01-AI38855NIAID NIH HHS U01-AI38858NIAID NIH HHS U01-AI42590NIAID NIH HHS U01-AI68634NIAID NIH HHS U01-AI68636NIAID NIH HHS U01-AI69432NIAID NIH HHS U01-AI69434NIAID NIH HHS UM1 AI035043NICHD NIH HHS U01-HD32632NIDA NIH HHS K24-DA00432NIDA NIH HHS R01-DA04334NIDA NIH HHS R01-DA11602NIDA NIH HHS R01-DA12568NIDA NIH HHS U01-DA036935NIMHD NIH HHS G12 MD007583NIMHD NIH HHS G12-MD007583NIMHD NIH HHS U54 MD007587NIMHD NIH HHS U54-MD007587NIMH NIH HHS K23-MH096647NIMH NIH HHS P30-MH62246PHS HHS 250-2012-00008CPHS HHS 290-2011-00007CPHS HHS 90047713PHS HHS 90051652PHS HHS CDC200-2011-41872PHS HHS K23-100700
6 · The paper itself

Abstract

The proportion of overweight and obese adults in the United States and Canada has increased over the past decade, but temporal trends in body mass index (BMI) and weight gain on antiretroviral therapy (ART) among HIV-infected adults have not been well characterized. We conducted a cohort study comparing HIV-infected adults in the North America AIDS Cohort Collaboration on Research and Design (NA-ACCORD) to United States National Health and Nutrition Examination Survey (NHANES) controls matched by sex, race, and age over the period 1998 to 2010. Multivariable linear regression assessed the relationship between BMI and year of ART initiation, adjusting for sex, race, age, and baseline CD4(+) count. Temporal trends in weight on ART were assessed using a generalized least-squares model further adjusted for HIV-1 RNA and first ART regimen class. A total of 14,084 patients from 17 cohorts contributed data; 83% were male, 57% were nonwhite, and the median age was 40 years. Median BMI at ART initiation increased from 23.8 to 24.8 kg/m(2) between 1998 and 2010 in NA-ACCORD, but the percentage of those obese (BMI ≥30 kg/m(2)) at ART initiation increased from 9% to 18%. After 3 years of ART, 22% of individuals with a normal BMI (18.5-24.9 kg/m(2)) at baseline had become overweight (BMI 25.0-29.9 kg/m(2)), and 18% of those overweight at baseline had become obese. HIV-infected white women had a higher BMI after 3 years of ART as compared to age-matched white women in NHANES (p = 0.02), while no difference in BMI after 3 years of ART was observed for HIV-infected men or non-white women compared to controls. The high prevalence of obesity we observed among ART-exposed HIV-infected adults in North America may contribute to health complications in the future.

Indexed as

AdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBlack or African AmericanBlack PeopleBody Mass IndexCanadaCD4 Lymphocyte CountCohort StudiesFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedNutrition SurveysAnti-HIV Agents

Identifiers

PMID26352511
PMCPMC4692122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.